Unique ID issued by UMIN | UMIN000031302 |
---|---|
Receipt number | R000035504 |
Scientific Title | Metachronous gastric cancer prevention with aspirin:A multi-center randomized trial |
Date of disclosure of the study information | 2018/02/14 |
Last modified on | 2020/04/10 14:41:15 |
Metachronous gastric cancer prevention with aspirin:A multi-center randomized trial
MEGA trial
Metachronous gastric cancer prevention with aspirin:A multi-center randomized trial
MEGA trial
Japan | Asia(except Japan) |
Patients who underwent endoscopic submucosal dissection (ESD) for early gastric cancer
Gastroenterology | Gastrointestinal surgery |
Malignancy
NO
We aim to test the hypothesis that aspirin can reduce the occurrence of metachronous gastric cancer after ESD.
Efficacy
Confirmatory
Cumulative incidence rate of metachronous gastric carcinoma at 5 years after ESD.
Adverse events rate
Histological evaluation of gastric mucosal atrophy and intestinal metaplasia
Microbiota changes in stool and oral swab
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
No treatment
2
Prevention
Medicine |
Aspirin 81 mg once daily for up to 5 years
Nothing
20 | years-old | <= |
80 | years-old | >= |
Male and Female
1) Achieved absolute or expanded curative resection with ESD defined as per JGCA guidelines
2) Aged 20-80 years
3) Performance Status (ECOG) 0, 1, or 2
4) H. pylori infection was eradicated within 5 years or negative before enrollment
5) Will be followed over 5 years
6) Written informed consent
1) Allergy to aspirin treatment
2) Other gastric neoplasm including low grade adenoma remain
3) A history of H. pylori eradication therapy received more than 5 years ago
4) Lesions of Siewert Type II (<2 cm from the OGJ at the epicenter)
5) A history of gastric surgery
6) Severe co-morbidities and estimated life expectancy less than 3 years
7) Already on aspirin or other antithrombotic drugs prior to randomization
8) Using NSAIDs
9) Using Metformin
10) A history of peptic ulcers
11) A history of stroke
12) Receiving chemotherapy
13) Disorder of blood coagulation or platelet < 100,000/microliter
14) Pregnancy
15) Breast-feeding
16) Lack of informed consent
1120
1st name | Takuji |
Middle name | |
Last name | Gotoda |
Nihon University School of Medicine
Division of Gastroenterology and Hepatology, Department of Medicine,
101-8309
1-6 Kanda-Surugadai, Chiyoda-ku, Tokyo, Japan
03-3293-1711
takujigotoda@yahoo.co.jp
1st name | Sho |
Middle name | |
Last name | Suzuki |
Nihon University School of Medicine
Division of Gastroenterology and Hepatology, Department of Medicine,
101-8309
1-6 Kanda-Surugadai, Chiyoda-ku, Tokyo, Japan
03-3293-1711
s.sho.salubriter.mail@gmail.com
MEGA trial Group
Japan Strategic Medical Administration Research Center: J-SMARC
Non profit foundation
Institutional Review Board of Nippon Medical School Foundation
1-1-5, Sendagi, Bunkyoku, Tokyo, Japan
03-5802-8202
officetokutei@nms.ac.jp
NO
2018 | Year | 02 | Month | 14 | Day |
Unpublished
50
Terminated
2019 | Year | 02 | Month | 04 | Day |
2019 | Year | 02 | Month | 25 | Day |
2019 | Year | 06 | Month | 01 | Day |
2027 | Year | 05 | Month | 31 | Day |
2018 | Year | 02 | Month | 14 | Day |
2020 | Year | 04 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000035504
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |